You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK):抗TIGIT單克隆抗體1期臨牀研究在中國完成首例患者給藥
格隆匯 05-26 07:05

格隆匯5月26日丨信達生物-B(01801.HK)發佈公告,公司的重組全人源抗含免疫球蛋白基序和免疫受體酪氨酸抑制基序結構域的T細胞免疫受體(TIGIT)單克隆抗體(IBI-939)的1期臨牀研究完成中國首例患者給藥。

IBI-939的1期臨牀研究是一項在中國開展,用以評估IBI-939單藥或聯合達伯舒® (信迪利單抗注射液),重組全人源抗PD-1單克隆抗體,治療晚期惡性腫瘤受試者中的安全性、耐受性和初步抗腫瘤有效性的臨牀研究。

TIGIT是腫瘤免疫治療中最有前景和潛力的靶點之一。目前,國外正在開展多個抗TIGIT單克隆抗體藥物相關的臨牀研究,但尚無品種被獲批。初步臨牀結果顯示,抗TIGIT抗體作為單藥療法或聯合抗PD-1/PD-L1抗體藥物均展現出一定的安全性和抗腫瘤有效性,特別是聯合療法有望發揮協同增強作用。IBI-939的1期臨牀研究是中國第一個靶向TIGIT藥物的臨牀研究。因此,開發針對TIGIT靶點的藥物具有重要臨牀意義,有可能為患者提供更新型和有效的治療方案。

IBI-939是公司開發的新型重組全人源抗TIGIT單克隆抗體。作為1類創新藥, IBI-939可以直接結合TIGIT,解除T細胞及NK細胞的抑制和耗竭,從而激活和提高T細胞及NK細胞的抗腫瘤免疫效應。IBI-939有望協同抗PD-1/PD-L1抗體提高抗腫瘤有效性,延緩耐藥性,可能為腫瘤患者提供更有效的治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account